Tildrakizumab in the treatment of psoriasis: latest evidence and place in therapy

Psoriasis is a chronic inflammatory disorder that is clinically characterized by scaly cutaneous plaques. New evidence suggests that dysregulation of interleukin (IL)-23, a key cytokine in the T-helper-17 pathway, plays a vital role in the development of psoriatic systemic inflammation. The novel bi...

Descripción completa

Detalles Bibliográficos
Autores principales: Pithadia, Deeti J., Reynolds, Kelly A., Lee, Erica B., Liao, Wilson, Wu, Jashin J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Psoriasis: From Pathophysiology to Treatment
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6691657/
https://www.ncbi.nlm.nih.gov/pubmed/31448070
http://dx.doi.org/10.1177/2040622319865658

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6691657/
https://www.ncbi.nlm.nih.gov/pubmed/31448070
http://dx.doi.org/10.1177/2040622319865658

Ejemplares similares